Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2025-12-24 @ 7:38 PM
NCT ID:
NCT00641303
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed invasive carcinoma of the breast
* Stage 0-III disease
* Estrogen receptor- and/or progesterone receptor-positive by immunohistochemical staining
* Must be receiving a standard dose of aromatase inhibitor (AI) therapy (i.e., letrozole 2.5 mg once daily, exemestane 25 mg once daily, or anastrozole 1 mg once daily)
* AI therapy has been ongoing for ≥ 1 month and treatment is expected to continue
* AI-associated musculoskeletal symptoms, defined as ≥ 1 of the following:
* Physician-confirmed AI-associated musculoskeletal symptoms
* Patients concurrently enrolled on the clinical trial, "A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism," and who have met the referral criteria for a rheumatological evaluation
* No known metastatic (stage IV) breast cancer
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Female
* Menopausal status not specified
PRIOR CONCURRENT THERAPY:
* No prior acupuncture within past 12 months.
* No other concurrent systemic therapy (i.e., chemotherapy, biologic therapy, or radiotherapy) unless approval is given by the Protocol Chair
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00641303
Study Brief:
Protocol Section:
NCT00641303